新型肺癌藥物獲歐盟核准
New Lung Cancer Drug Receives EU Validation
醫學研究邁出了積極的一步，歐洲藥品管理局（EMA）近期通過了一項新型癌症療法的申請驗證。
Medical science has taken a positive step forward as the European Medicines Agency (EMA) recently validated an application for a new cancer treatment.
2026年3月，該機構確認，用於治療晚期ROS1陽性非小細胞肺癌（NSCLC）的藥物taletrectinib之申請已完成，並準備進行正式科學評審。
In March 2026, the agency confirmed that the application for taletrectinib, a drug designed for advanced ROS1-positive non-small cell lung cancer (NSCLC), is complete and ready for a formal scientific review.
Taletrectinib是一種次世代口服酪胺酸激酶抑制劑，已在美國、中國和日本取得了成功。
Taletrectinib is a next-generation oral tyrosine kinase inhibitor that has already seen success in the United States, China, and Japan.
這項進展是精準醫學趨勢中的一部分，該領域針對腫瘤中發現的特定基因突變來量身訂製治療方案。
This development is part of a growing trend in precision medicine, where treatments are tailored to specific genetic mutations found in tumors.
此次申請獲得了TRUST-I和TRUST-II臨床試驗的支持，旨在為歐洲患者提供一種新的治療選擇。
The filing, supported by the TRUST-I and TRUST-II clinical trials, aims to provide a new therapeutic option for patients in Europe.
雖然醫學界正在等待EMA人用醫藥產品委員會的最終意見，但這一進展為在抗擊肺癌過程中需要更專業護理的患者帶來了希望。
While the medical community awaits the final opinion from the EMA's Committee for Medicinal Products for Human Use, this progress offers hope for patients who need more specialized care in the fight against lung cancer.
